The goals of the Association for Molecular Pathology (AMP) Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

Recent advances in next-generation sequencing (NGS) have resulted in the identification of
tens of thousands of rare pharmacogenetic variations with unknown functional effects …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Preemptive targeted pharmacogenetic testing of candidate variations in DPYD is currently
being used to limit toxicity associated with fluoropyrimidines. The use of innovative next …

Pharmacogenomics (PGx) studies the use of genetic data to optimize drug therapy.
Numerous clinical centers have commenced implementing pharmacogenetic tests in clinical …

Simple Summary 5-Fluorouracil (5-FU) is a chemotherapy drug that is commonly used to
treat multiple cancers. Many people who are treated with 5-FU experience severe toxicity to …

PURPOSE Patients who carry pathogenic variants in DPYD have higher systemic
fluoropyrimidine (FP) concentrations and greater risk of severe and fatal FP toxicity …

Fluoropyrimidines (FLs)[5-Fluorouracil, Capecitabine] are used in the treatment of several
solid tumors. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for FL …

Genetic and other variations frequently affect protein functions. Scientific articles can contain
confusing descriptions about which function or property is affected, and in many cases the …

Background Inter-individual differences in dihydropyrimidine dehydrogenase (DPYD
encoding DPD) and thiopurine S-methyltransferase (TPMT) activity are important predictors …